DBT to fund research for developing affordable drug resistant TB diagnostics

TB Diagnostic manufacturers are eligible to recieve the funding from the Indian government for development of innovative, field-applicable and cost-effective diagnostic biomarkers

0
832
Image-Tuberculosis bacteria.

New Delhi: The rapidly spreading multidrug resistant (MDR) and extensively drug resistant (XDR) Tuberculosis (TB) in the country has left the policy makers worried about the challenge to develop early and species specific diagnosis of tuberculosis. Also, the other major problem is with the detection of its drug resistance pattern so that most appropriate treatment can be started and further transmission can be contained.

Taking a step in this direction, the Department of Biotechnology, Ministry of Science and Technology, Government of India has solicited research and development (R&D) proposals from TB Diagnostic manufactureres for development of innovative, field-applicable and cost-effective diagnostic biomarkers. Last Date of submission of proposals is May 31, 2016.

The major thrust areas include:

  • Innovative and highly specific point of care test to rule out tuberculosis or a highly sensitive screening test (Triage Test).
  • Diagnostic tests for pediatric tuberculosis.
  • Rapid tests to detect and differentiate non-tuberculous Mycobacteria from M. tuberculosis directly in clinical samples.
  • Diagnosis of extra-pulmonary tuberculosis (EPTB) using alternative samples such as whole blood, serum/plasma, urine, sweat etc.
  • Diagnostic markers for prognosis and treatment outcome (cure or treatment failure).
  • Host/mycobacterial biomarkers to predict the clinical disease from latent infection.
  • Biomarkers of treatment compliance/ non-compliance.

While submitting the R & D proposal, investigators should use format available at http://dbtindia.nic.in and submit 5 hard copies of full length proposals duly forwarded by the competent authority by post to Dr Sandhya R. Shenoy, Joint Director, Department of Biotechnology. Corresponding online application should be submitted through the ePromis window at www.dbtepromis.nic.in under the area ‘Medical Biotechnology – Non-Infectious Diseases, Chronic Disease Biology’ which is mandatory.

Aspirants of funding can also open DBT epromis website http://dbtepromis.nic.in/login.aspx and consult the user manual for project Investigator and thereafter go ahead with the submission process under the Programme Area: ’Medical Biotechnology – Non-Infectious Diseases, Chronic Disease Biology’.